BRISTOL MYERS SQUIBB
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Phase III Study of Abatacept in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2006-12-11
- Last Posted Date
- 2013-08-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 113
- Registration Number
- NCT00409838
- Locations
- ๐ฐ๐ท
Local Institution, Seoul, Korea, Republic of
A Study of Abatacept in Patients With Active Crohn's Disease
- First Posted Date
- 2006-12-04
- Last Posted Date
- 2010-09-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 451
- Registration Number
- NCT00406653
- Locations
- ๐บ๐ธ
Allegheny Center For Digestive Health, Pittsburgh, Pennsylvania, United States
๐บ๐ธConsultants For Clinical Research, Cincinnati, Ohio, United States
๐บ๐ธNashville Medical Research, Nashville, Tennessee, United States
A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids
- Conditions
- Renal Transplant
- Interventions
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2017-01-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 173
- Registration Number
- NCT00402168
- Locations
- ๐ช๐ธ
Local Institution, Valencia, Spain
๐ฉ๐ชCharite Berlin Mitte, Berlin, Germany
๐บ๐ธMayo Clinic Hospital, Phoenix, Arizona, United States
Drug Interaction - Oral Contraceptive
- Conditions
- HIV Infections
- Interventions
- Drug: Ortho CyclenDrug: Ortho Tri-Cyclen LODrug: Ortho Cyclen + Efavirenz
- First Posted Date
- 2006-11-15
- Last Posted Date
- 2011-04-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 28
- Registration Number
- NCT00399685
- Locations
- ๐บ๐ธ
Covance Clinical Research Unit San Diego, San Diego, California, United States
๐บ๐ธNorthwest Kinetics, Tacoma, Washington, United States
A Study of BMS-582949 in Patients With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2006-11-15
- Last Posted Date
- 2015-12-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 99
- Registration Number
- NCT00399906
- Locations
- ๐ฒ๐ฝ
Local Institution, Monterrey, Nuevo Leon, Mexico
A Study of BMS-562086 in Patients With Irritable Bowel Syndrome
- First Posted Date
- 2006-11-14
- Last Posted Date
- 2008-09-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 39
- Registration Number
- NCT00399438
- Locations
- ๐บ๐ธ
Mayo Clinic, Rochester, Minnesota, United States
A Multiple Ascending Dose Study of BMS-707035 in HIV-1 Infected Subjects
- Conditions
- HIV Infections
- First Posted Date
- 2006-11-09
- Last Posted Date
- 2012-04-27
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00397566
Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection
- First Posted Date
- 2006-11-02
- Last Posted Date
- 2012-05-31
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 109
- Registration Number
- NCT00395018
- Locations
- ๐บ๐ธ
University Of Nebraska Medical Center, Omaha, Nebraska, United States
๐บ๐ธTulane University Hospital & Clinic, New Orleans, Louisiana, United States
๐บ๐ธBaylor College Of Medicine, Houston, Texas, United States
Bioequivalence Study of Atazanavir 300 mg Capsule
- First Posted Date
- 2006-10-27
- Last Posted Date
- 2011-04-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 46
- Registration Number
- NCT00393328
- Locations
- ๐บ๐ธ
Local Institution, Hamilton, New Jersey, United States
A Study in Korea of Entecavir Versus Lamivudine in Adults With Chronic Hepatitis B Infection
- Conditions
- Chronic Hepatitis B
- Interventions
- First Posted Date
- 2006-10-27
- Last Posted Date
- 2014-11-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 122
- Registration Number
- NCT00393484
- Locations
- ๐ฐ๐ท
Local Institution, Seoul, Korea, Republic of